Genmab

This early-stage trial is testing a new cancer drug called GEN1106 in people with advanced solid tumors, particularly bladder cancer that has spread. The study aims to find safe doses and see if the drug helps shrink tumors in patients who have already tried standard treatments. …

This is the first human trial of an experimental antibody called GEN3018 for adults with advanced blood cancers that have returned or resisted previous treatments. The main goals are to find a safe dose and see if the drug shows early signs of fighting the cancer. Up to 78 partic…

This study is testing whether combining a new drug called epcoritamab with other cancer medications can help control aggressive Non-Hodgkin Lymphoma. Researchers will enroll 496 adults whose cancer has returned after previous treatments or who are newly diagnosed. The main goal i…

This is the first human trial testing an experimental antibody called GEN1079 in people with advanced solid tumors. The study aims to find safe doses and see early signs of whether the treatment helps control cancer. About 121 participants with specific advanced cancers will rece…

This large, late-stage study is testing whether adding an investigational drug called Rina-S to standard care helps control recurrent ovarian cancer for longer after second-line chemotherapy. It will enroll about 528 women whose cancer returned more than 6 months after their firs…

This is the first-ever study in humans of an experimental antibody called GEN1057 for treating advanced solid tumors. The trial aims to find a safe dose and see early signs of whether the treatment can shrink tumors. It will enroll about 45 adults with metastatic or advanced canc…

This study is testing whether a new drug called Rina-S works better than standard chemotherapy options for women whose endometrial cancer has returned or worsened after prior treatment. About 544 participants will be randomly assigned to receive either Rina-S or one of two standa…

This study is testing whether a new drug combination (epcoritamab plus lenalidomide) works better than standard treatment for adults with aggressive lymphoma that has returned or hasn't responded to previous therapies. About 360 participants worldwide will receive either the new …

This study is testing whether a new drug called Rina-S can help control advanced non-small cell lung cancer. About 240 people worldwide with this type of lung cancer will receive the drug directly—no one gets a placebo. Researchers will monitor how well the drug shrinks tumors an…

This large, late-stage trial is testing whether adding a new drug, epcoritamab, to a standard treatment (rituximab and lenalidomide) works better and is safer than standard chemotherapy for adults newly diagnosed with follicular lymphoma. Follicular lymphoma is a common, slow-gro…

This study is testing a new drug called Rina-S in people whose solid tumor cancers have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for people with several types of advanced cancer, including ovarian,…